- Home
- NMRA vs LIEN Comparison
NMRA vs LIEN Comparison
Compare NMRA & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- LIEN
- Stock Information
- Founded
- NMRA 2019
- LIEN 2021
- Country
- NMRA United States
- LIEN United States
- Employees
- NMRA N/A
- LIEN N/A
- Industry
- NMRA
- LIEN
- Sector
- NMRA
- LIEN
- Exchange
- NMRA Nasdaq
- LIEN NYSE
- Market Cap
- NMRA 121.0M
- LIEN 234.6M
- IPO Year
- NMRA 2023
- LIEN 2022
- Fundamental
- Price
- NMRA $0.84
- LIEN $10.22
- Analyst Decision
- NMRA Buy
- LIEN Buy
- Analyst Count
- NMRA 8
- LIEN 2
- Target Price
- NMRA $9.29
- LIEN N/A
- AVG Volume (30 Days)
- NMRA 1.4M
- LIEN 63.2K
- Earning Date
- NMRA 08-05-2025
- LIEN 08-07-2025
- Dividend Yield
- NMRA N/A
- LIEN 13.31%
- EPS Growth
- NMRA N/A
- LIEN 30.25
- EPS
- NMRA N/A
- LIEN 1.15
- Revenue
- NMRA N/A
- LIEN $30,828,508.00
- Revenue This Year
- NMRA N/A
- LIEN $154.46
- Revenue Next Year
- NMRA N/A
- LIEN $10.64
- P/E Ratio
- NMRA N/A
- LIEN $8.86
- Revenue Growth
- NMRA N/A
- LIEN 151.96
- 52 Week Low
- NMRA $0.61
- LIEN $9.70
- 52 Week High
- NMRA $17.19
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- NMRA 52.19
- LIEN N/A
- Support Level
- NMRA $0.72
- LIEN N/A
- Resistance Level
- NMRA $0.85
- LIEN N/A
- Average True Range (ATR)
- NMRA 0.07
- LIEN 0.00
- MACD
- NMRA -0.01
- LIEN 0.00
- Stochastic Oscillator
- NMRA 62.35
- LIEN 0.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.